Psyence BioMed Exercises Put Option to Invest in PsyLabs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PBM?
Source: Newsfilter
- Equity Investment Agreement: Psyence BioMed will make an equity investment in PsyLabs under a previously disclosed put option agreement, which is expected to enhance strategic alignment between the two companies and support Psyence BioMed's long-term supply strategy.
- Transaction Details: The deal involves Psyence BioMed acquiring 2,900 shares of PsyLabs for a subscription amount of $5 million, reflecting a fair market valuation of $1,724 per share, while PsyLabs will receive 1,146,159 PBM shares calculated at a 30-day VWAP of $4.36 per share.
- Shareholder Structure Change: Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed's shares, which could significantly influence governance and control dynamics, increasing its impact on shareholder decisions.
- Strategic Implications: This investment reflects the ongoing evolution of the strategic relationship between the parties and underscores Psyence BioMed's commitment to securing high-quality pharmaceutical manufacturing capabilities to support its clinical and commercialization programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Psyence BioMed Exercises Put Option to Invest in PsyLabs
- Equity Investment Agreement: Psyence BioMed will make an equity investment in PsyLabs under a previously disclosed put option agreement, which is expected to enhance strategic alignment between the two companies and support Psyence BioMed's long-term supply strategy.
- Transaction Details: The deal involves Psyence BioMed acquiring 2,900 shares of PsyLabs for a subscription amount of $5 million, reflecting a fair market valuation of $1,724 per share, while PsyLabs will receive 1,146,159 PBM shares calculated at a 30-day VWAP of $4.36 per share.
- Shareholder Structure Change: Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed's shares, which could significantly influence governance and control dynamics, increasing its impact on shareholder decisions.
- Strategic Implications: This investment reflects the ongoing evolution of the strategic relationship between the parties and underscores Psyence BioMed's commitment to securing high-quality pharmaceutical manufacturing capabilities to support its clinical and commercialization programs.
See More
Psyence BioMed Announces Shareholder Meeting Voting Results
- Voting Results: Psyence BioMed held its Annual Meeting on February 12, 2026, where all proposals, including director elections and auditor appointments, were approved, indicating strong shareholder support for corporate governance.
- Auditor Appointment: Shareholders approved MNP LLP as the company's auditors for the upcoming year and authorized the Board to determine the auditors' remuneration, ensuring financial transparency and compliance.
- Share Consolidation Authorization: A special resolution was passed allowing the Board to implement share consolidations of up to 250:1, which could impact the company's capital structure and enhance per-share value.
- Future Disclosure Commitment: The company committed to providing further details regarding the share consolidation, including the final ratio and effective date, ensuring shareholders are informed about significant decisions.
See More
Psyence BioMed Enters Put Option Agreement with PsyLabs
- Strategic Partnership: Psyence BioMed's put option agreement with PsyLabs allows the latter to request equity investment at fair market value, enhancing collaboration potential in the mental health sector.
- Supply Chain Assurance: The agreement secures Psyence's access to high-quality pharmaceutical-grade psychedelics, supporting future clinical and commercial programs while mitigating supply chain and regulatory risks.
- Financial Flexibility: The put option structure enables Psyence to maintain financial flexibility without needing to deploy significant capital upfront, optimizing cash use for clinical and regulatory execution.
- Independent Review Mechanism: The company's board established a special committee of two independent directors to review and ratify the agreement, ensuring commercial rationale and transparency, thereby strengthening corporate governance.
See More
Psyence Biomedical Settles Shareholder Claim for $1.5 Million
- Settlement Agreement: Psyence Biomedical has entered into a settlement agreement with KAOS Capital, agreeing to pay $1.5 million to resolve a shareholder claim made in January 2026, despite the company denying all allegations as unfounded.
- Court Ruling Impact: On January 21, 2026, the Ontario Superior Court dismissed KAOS's application and ordered it to pay the company CAD $75,000 in costs, demonstrating judicial support for the company's position and reducing potential legal expenses and business disruptions.
- Shareholder Share Handling: Under the settlement terms, KAOS agrees to sell all common shares it holds at $5 per share to a third party designated by the company, which will help the company streamline its shareholder structure and stabilize its stock price.
- Financial Impact Assessment: The company expects to fund the settlement from cash on hand and record it in accordance with applicable accounting standards; although denying any wrongdoing, the decision to settle aims to avoid further litigation and associated costs.
See More
PSYENCE BIOMEDICAL LTD TO PAY KAOS CAPITAL $1.5 MILLION IN SETTLEMENT
- Settlement Amount: A biomedical company, Cotopay, has agreed to a settlement of $1.5 million.
- Context of Settlement: The settlement is related to a legal issue involving the company, although specific details of the case are not provided.
See More
Teradyne Q4 Earnings Beat Estimates, Shares Surge
- Earnings Surprise: Teradyne's fourth-quarter earnings report exceeded market expectations on both revenue and earnings per share, leading to a 22.2% surge in pre-market trading to $305.00, indicating strong investor confidence in its financial performance.
- Optimistic Outlook: The company forecasts first-quarter adjusted EPS between $1.89 and $2.25, significantly above the analyst estimate of $1.24, showcasing robust profitability and market demand.
- Revenue Projections Raised: Teradyne anticipates first-quarter revenue in the range of $1.15 billion to $1.25 billion, well above the analyst expectation of $927.72 million, reflecting the company's competitive edge and growth potential in the market.
- Positive Market Reaction: The substantial increase in stock price not only reflects investor approval of the company's performance but may also attract more institutional investors, potentially driving further stock price appreciation.
See More
Psyence BioMed Exercises Put Option to Invest in PsyLabs
- Equity Investment Agreement: Psyence BioMed will make an equity investment in PsyLabs under a previously disclosed put option agreement, which is expected to enhance strategic alignment between the two companies and support Psyence BioMed's long-term supply strategy.
- Transaction Details: The deal involves Psyence BioMed acquiring 2,900 shares of PsyLabs for a subscription amount of $5 million, reflecting a fair market valuation of $1,724 per share, while PsyLabs will receive 1,146,159 PBM shares calculated at a 30-day VWAP of $4.36 per share.
- Shareholder Structure Change: Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed's shares, which could significantly influence governance and control dynamics, increasing its impact on shareholder decisions.
- Strategic Implications: This investment reflects the ongoing evolution of the strategic relationship between the parties and underscores Psyence BioMed's commitment to securing high-quality pharmaceutical manufacturing capabilities to support its clinical and commercialization programs.
See More
Psyence BioMed Announces Shareholder Meeting Voting Results
- Voting Results: Psyence BioMed held its Annual Meeting on February 12, 2026, where all proposals, including director elections and auditor appointments, were approved, indicating strong shareholder support for corporate governance.
- Auditor Appointment: Shareholders approved MNP LLP as the company's auditors for the upcoming year and authorized the Board to determine the auditors' remuneration, ensuring financial transparency and compliance.
- Share Consolidation Authorization: A special resolution was passed allowing the Board to implement share consolidations of up to 250:1, which could impact the company's capital structure and enhance per-share value.
- Future Disclosure Commitment: The company committed to providing further details regarding the share consolidation, including the final ratio and effective date, ensuring shareholders are informed about significant decisions.
See More
Psyence BioMed Enters Put Option Agreement with PsyLabs
- Strategic Partnership: Psyence BioMed's put option agreement with PsyLabs allows the latter to request equity investment at fair market value, enhancing collaboration potential in the mental health sector.
- Supply Chain Assurance: The agreement secures Psyence's access to high-quality pharmaceutical-grade psychedelics, supporting future clinical and commercial programs while mitigating supply chain and regulatory risks.
- Financial Flexibility: The put option structure enables Psyence to maintain financial flexibility without needing to deploy significant capital upfront, optimizing cash use for clinical and regulatory execution.
- Independent Review Mechanism: The company's board established a special committee of two independent directors to review and ratify the agreement, ensuring commercial rationale and transparency, thereby strengthening corporate governance.
See More
Psyence Biomedical Settles Shareholder Claim for $1.5 Million
- Settlement Agreement: Psyence Biomedical has entered into a settlement agreement with KAOS Capital, agreeing to pay $1.5 million to resolve a shareholder claim made in January 2026, despite the company denying all allegations as unfounded.
- Court Ruling Impact: On January 21, 2026, the Ontario Superior Court dismissed KAOS's application and ordered it to pay the company CAD $75,000 in costs, demonstrating judicial support for the company's position and reducing potential legal expenses and business disruptions.
- Shareholder Share Handling: Under the settlement terms, KAOS agrees to sell all common shares it holds at $5 per share to a third party designated by the company, which will help the company streamline its shareholder structure and stabilize its stock price.
- Financial Impact Assessment: The company expects to fund the settlement from cash on hand and record it in accordance with applicable accounting standards; although denying any wrongdoing, the decision to settle aims to avoid further litigation and associated costs.
See More
PSYENCE BIOMEDICAL LTD TO PAY KAOS CAPITAL $1.5 MILLION IN SETTLEMENT
- Settlement Amount: A biomedical company, Cotopay, has agreed to a settlement of $1.5 million.
- Context of Settlement: The settlement is related to a legal issue involving the company, although specific details of the case are not provided.
See More
Teradyne Q4 Earnings Beat Estimates, Shares Surge
- Earnings Surprise: Teradyne's fourth-quarter earnings report exceeded market expectations on both revenue and earnings per share, leading to a 22.2% surge in pre-market trading to $305.00, indicating strong investor confidence in its financial performance.
- Optimistic Outlook: The company forecasts first-quarter adjusted EPS between $1.89 and $2.25, significantly above the analyst estimate of $1.24, showcasing robust profitability and market demand.
- Revenue Projections Raised: Teradyne anticipates first-quarter revenue in the range of $1.15 billion to $1.25 billion, well above the analyst expectation of $927.72 million, reflecting the company's competitive edge and growth potential in the market.
- Positive Market Reaction: The substantial increase in stock price not only reflects investor approval of the company's performance but may also attract more institutional investors, potentially driving further stock price appreciation.
See More
